Literature DB >> 28659311

Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.

Lucía Fernández1,2, Jean-Yves Metais3, Adela Escudero2,4, María Vela2, Jaime Valentín2, Isabel Vallcorba4, Alejandra Leivas1,5, Juan Torres6,7, Antonio Valeri5, Ana Patiño-García8, Joaquín Martínez1,5, Wing Leung9, Antonio Pérez-Martínez10,11.   

Abstract

Purpose: NKG2D ligands (NKG2DL) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy. Various immune cells express NKG2D receptors, including natural killer (NK) cells and CD8+ T cells. Interactions between NKG2DL and NKG2D receptors are essential for NK-cell elimination of osteosarcoma tumor-initiating cells. In this report, we used NKG2D-NKG2DL interactions to optimize an immunotherapeutic strategy against osteosarcoma. We evaluated in vitro and in vivo the safety and cytotoxic capacity against osteosarcoma cells of CD45RA- memory T cells expressing an NKG2D-4-1BB-CD3z chimeric antigen receptor (CAR).Experimental Design: CD45RA- cells from healthy donors were transduced with NKG2D CARs containing 4-1BB and CD3z signaling domains. NKG2D CAR expression was analyzed by flow cytometry. In vitro cytotoxicity of NKG2D-CAR+ CD45RA- T cells against osteosarcoma was evaluated by performing conventional 4-hour europium-TDA release assays. For the in vivo orthotopic model, 531MII YFP-luc osteosarcoma cells were used as targets in NOD-scid IL2Rgnull mice.
Results: Lentiviral transduction of NKG2D-4-1BB-CD3z markedly increased NKG2D surface expression in CD45RA- cells. Genetic stability was preserved in transduced cells. In vitro, NKG2D-CAR+ memory T cells showed significantly increased cytolytic activity than untransduced cells against osteosarcoma cell lines, while preserving the integrity of healthy cells. NKG2D-CAR+ memory T cells had considerable antitumor activity in a mouse model of osteosarcoma, whereas untransduced T cells were ineffective.Conclusions: Our results demonstrate NKG2D-4-1BB-CD3z CAR-redirected memory T cells target NKG2DL-expressing osteosarcoma cells in vivo and in vitro and could be a promising immunotherapeutic approach for patients with osteosarcoma. Clin Cancer Res; 23(19); 5824-35. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28659311     DOI: 10.1158/1078-0432.CCR-17-0075

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

Review 2.  Acute myeloid leukemia and NK cells: two warriors confront each other.

Authors:  Aroa Baragaño Raneros; Carlos López-Larrea; Beatriz Suárez-Álvarez
Journal:  Oncoimmunology       Date:  2018-10-31       Impact factor: 8.110

Review 3.  NKG2D and its ligands in cancer.

Authors:  Payal Dhar; Jennifer D Wu
Journal:  Curr Opin Immunol       Date:  2018-03-09       Impact factor: 7.486

4.  Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.

Authors:  Xiuxia Lu; Mengmeng Liu; Jing Yang; Yi Que; Xing Zhang
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 5.  Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

Authors:  Tianyi Zhu; Jing Han; Liu Yang; Zhengdong Cai; Wei Sun; Yingqi Hua; Jing Xu
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 6.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

Review 7.  Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Authors:  V Leuci; G M Casucci; G Grignani; R Rotolo; U Rossotti; E Vigna; L Gammaitoni; G Mesiano; E Fiorino; C Donini; A Pisacane; L D Ambrosio; Y Pignochino; M Aglietta; A Bondanza; D Sangiolo
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

9.  Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.

Authors:  Javier Valdés-Ferrada; Natalia Muñoz-Durango; Alejandra Pérez-Sepulveda; Sabrina Muñiz; Irenice Coronado-Arrázola; Francisco Acevedo; Jorge A Soto; Susan M Bueno; Cesar Sánchez; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

Review 10.  Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.

Authors:  J Obajdin; D M Davies; J Maher
Journal:  Clin Exp Immunol       Date:  2020-07-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.